Cargando…
The neurobiology and treatment of first-episode schizophrenia
It is evident that once psychosis is present in patients with schizophrenia, the underlying biological process of the illness has already been ongoing for many years. At the time of diagnosis, patients with schizophrenia show decreased mean intracranial volume (ICV) as compared with healthy subjects...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320288/ https://www.ncbi.nlm.nih.gov/pubmed/25048005 http://dx.doi.org/10.1038/mp.2014.66 |
_version_ | 1782356099454730240 |
---|---|
author | Kahn, R S Sommer, I E |
author_facet | Kahn, R S Sommer, I E |
author_sort | Kahn, R S |
collection | PubMed |
description | It is evident that once psychosis is present in patients with schizophrenia, the underlying biological process of the illness has already been ongoing for many years. At the time of diagnosis, patients with schizophrenia show decreased mean intracranial volume (ICV) as compared with healthy subjects. Since ICV is driven by brain growth, which reaches its maximum size at approximately 13 years of age, this finding suggests that brain development in patients with schizophrenia is stunted before that age. The smaller brain volume is expressed as decrements in both grey and white matter. After diagnosis, it is mainly the grey matter loss that progresses over time whereas white matter deficits are stable or may even improve over the course of the illness. To understand the possible causes of the brain changes in the first phase of schizophrenia, evidence from treatment studies, postmortem and neuroimaging investigations together with animal experiments needs to be incorporated. These data suggest that the pathophysiology of schizophrenia is multifactorial. Increased striatal dopamine synthesis is already evident before the time of diagnosis, starting during the at-risk mental state, and increases during the onset of frank psychosis. Cognitive impairment and negative symptoms may, in turn, result from other abnormalities, such as NMDA receptor hypofunction and low-grade inflammation of the brain. The latter two dysfunctions probably antedate increased dopamine synthesis by many years, reflecting the much earlier presence of cognitive and social dysfunction. Although correction of the hyperdopaminergic state with antipsychotic agents is generally effective in patients with a first-episode psychosis, the effects of treatments to correct NMDA receptor hypofunction or low-grade inflammation are (so far) rather modest at best. Improved efficacy of these interventions can be expected when they are applied at the onset of cognitive and social dysfunction, rather than at the onset of psychosis. |
format | Online Article Text |
id | pubmed-4320288 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-43202882015-02-17 The neurobiology and treatment of first-episode schizophrenia Kahn, R S Sommer, I E Mol Psychiatry Expert Review It is evident that once psychosis is present in patients with schizophrenia, the underlying biological process of the illness has already been ongoing for many years. At the time of diagnosis, patients with schizophrenia show decreased mean intracranial volume (ICV) as compared with healthy subjects. Since ICV is driven by brain growth, which reaches its maximum size at approximately 13 years of age, this finding suggests that brain development in patients with schizophrenia is stunted before that age. The smaller brain volume is expressed as decrements in both grey and white matter. After diagnosis, it is mainly the grey matter loss that progresses over time whereas white matter deficits are stable or may even improve over the course of the illness. To understand the possible causes of the brain changes in the first phase of schizophrenia, evidence from treatment studies, postmortem and neuroimaging investigations together with animal experiments needs to be incorporated. These data suggest that the pathophysiology of schizophrenia is multifactorial. Increased striatal dopamine synthesis is already evident before the time of diagnosis, starting during the at-risk mental state, and increases during the onset of frank psychosis. Cognitive impairment and negative symptoms may, in turn, result from other abnormalities, such as NMDA receptor hypofunction and low-grade inflammation of the brain. The latter two dysfunctions probably antedate increased dopamine synthesis by many years, reflecting the much earlier presence of cognitive and social dysfunction. Although correction of the hyperdopaminergic state with antipsychotic agents is generally effective in patients with a first-episode psychosis, the effects of treatments to correct NMDA receptor hypofunction or low-grade inflammation are (so far) rather modest at best. Improved efficacy of these interventions can be expected when they are applied at the onset of cognitive and social dysfunction, rather than at the onset of psychosis. Nature Publishing Group 2015-02 2014-07-22 /pmc/articles/PMC4320288/ /pubmed/25048005 http://dx.doi.org/10.1038/mp.2014.66 Text en Copyright © 2015 Macmillan Publishers Limited http://creativecommons.org/licenses/by/3.0/ This work is licensed under a Creative Commons Attribution 3.0 Unported License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/3.0/ |
spellingShingle | Expert Review Kahn, R S Sommer, I E The neurobiology and treatment of first-episode schizophrenia |
title | The neurobiology and treatment of first-episode schizophrenia |
title_full | The neurobiology and treatment of first-episode schizophrenia |
title_fullStr | The neurobiology and treatment of first-episode schizophrenia |
title_full_unstemmed | The neurobiology and treatment of first-episode schizophrenia |
title_short | The neurobiology and treatment of first-episode schizophrenia |
title_sort | neurobiology and treatment of first-episode schizophrenia |
topic | Expert Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320288/ https://www.ncbi.nlm.nih.gov/pubmed/25048005 http://dx.doi.org/10.1038/mp.2014.66 |
work_keys_str_mv | AT kahnrs theneurobiologyandtreatmentoffirstepisodeschizophrenia AT sommerie theneurobiologyandtreatmentoffirstepisodeschizophrenia AT kahnrs neurobiologyandtreatmentoffirstepisodeschizophrenia AT sommerie neurobiologyandtreatmentoffirstepisodeschizophrenia |